Lexicon Pharmaceuticals, Inc. (LXRX): Insiders Aren't Crazy About It
In the 21st century investor’s toolkit, there are a multitude of metrics investors can use to monitor stocks. A duo of the best are hedge fund and insider trading activity.
Lexicon Pharmaceuticals Inc. (LXRX)
Market is closed
News
- First
- << Previous
- 41 - 47
Is Nektar Therapeutics (NKTR) Going to Burn These Hedge Funds?
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds' portfolio at the end of March. NKTR has experienced a decrease in support from the world's most elite money managers in recent months.
Amarin Corporation plc (ADR) (AMRN), Lexicon Pharmaceuticals, Inc. (LXRX): Which of These Billion-Dollar Biotechs Is a Buy?
It has been a rough year for Amarin Corporation plc (ADR) (NASDAQ:AMRN) and its long-term investors.
Santarus, Inc. (SNTS): Insiders Are Buying, Should You?
If you'd ask most shareholders, hedge funds are assumed to be underperforming, old investment tools of the past.
This Metric Says You Are Smart to Buy Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds' portfolio at the end of March. SRPT shareholders have witnessed an increase in enthusiasm from smart money in recent months.
Acorda Therapeutics Inc (ACOR): Insiders Are Dumping, Should You?
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds' portfolio at the end of the fourth quarter of 2012.
Pacific Biosciences of California (PACB), Lexicon Pharmaceuticals, Inc. (LXRX): 3 Stocks With Insider Interest
The global economy is still going through the initial stages of recovery and waiting on positive news from European markets.
- First
- << Previous
- 41 - 47
Billionaire Hedge Funds
